Press release: invIOs to present progress across oncology pipeline during JP Morgan Week 2025
Vienna, Austria, 16 December 2024: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in San Francisco, January...
December 16, 2024
No Comments
Press Release: invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology
Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute (DFCI) making good progress; target validation and details of…
October 15, 2024
No Comments
Press release: We are proud to announce that invIOs has selected INV501’s lead candidate to progress into IND-enabling studies in glioblastoma and melanoma.
This is particularly fitting as today is Glioblastoma Awareness Day, to recognize the impact of this most aggressive form of brain cancer and highlight the need to advance research, raise...
July 17, 2024
No Comments
Three questions to Prof. Gottfried Baier
1. New immunotherapeutic drugs such as CAR-T cells can benefit patients with certain blood cancers such as leukemia, lymphoma and multiple myeloma. What are the main reasons that the use...
December 18, 2023
No Comments
Press release: invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
• Preclinical study will be conducted by Dr. David Reardon’s research group • Immune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer Vienna, Austria and Boston,…
November 10, 2023
No Comments
Press release: invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started; invIOs awarded up to 45% funding of trial…
September 5, 2023
No Comments
invIOs’s EPiC cell therapy platform to progress development of novel CAR-T cell approach against lung cancer with Medical University of Innsbruck
invIOs is teaming up with the Medical University of Innsbruck on a new project to investigate the potential of an innovative CAR-T cell therapy approach to treat aggressive lung tumors....
July 5, 2023
No Comments
Press release: invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors
INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indications Treatment with INV501 significantly inhibits tumor growth, extends survival and increases cure...
June 16, 2023
No Comments
